The best human trial concluded it probably does not, and the trial authors said so themselves.
Delta sleep-inducing peptide has a real human research record, unusual for a compound sold this way. It is also small, old, and delivered by a route almost nobody uses.
The strongest study against it is a double-blind trial in 16 chronic insomniacs, with polysomnography and a placebo arm, run by a group independent of DSIP's discoverers. It found higher sleep efficiency and shorter sleep latency on DSIP. Then its own authors wrote that the significant effects were weak, that part of the difference may have come from an incidental change in the placebo group, and that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.1
That is the compound's best evidence, described by the people who produced it.
Two other things worth knowing before the threads make sense. Both trials covered here gave DSIP intravenously, and people inject it under the skin. And the paradoxical wakefulness people report is in the data: the 1981 study recorded a slight arousing effect in the first hour after injection, with sleep-promoting effects only in the second.2
What did the human trials on DSIP find?
Mostly positive results from one research group, and a weaker result from a different one.
The human sleep studies run from 1981 to 1992, are all small, and are all intravenous. Most come from Dietrich Schneider-Helmert and colleagues in Switzerland, the group connected to DSIP's original discovery.2
| Study | People | Design | Result |
|---|---|---|---|
| Schneider-Helmert 1981 | 6 chronic insomniacs | Open | Longer sleep, fewer interruptions, more REM, no sedation2 |
| Schneider-Helmert 1986 | 18 chronic insomniacs | Not stated in abstract | Sleep normalised in middle-aged and older groups |
| Schneider-Helmert 1987 | 14 chronic insomniacs | Double-blind, placebo-controlled, 7 nights | Sleep efficiency raised to the level of normal controls4 |
| Bes et al. 1992 | 16 chronic insomniacs | Double-blind, matched pairs, parallel groups | Weak objective gains, no subjective change, authors concluded against1 |
The last row is a different research group, working in Amsterdam, publishing the study that concluded short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.1
That is the shape of a replication problem. A compound produces encouraging results in the hands of the people who discovered it, and a weaker result when a separate group runs a blinded trial.
What the 1992 study actually found, since the detail matters. Sixteen patients, five consecutive nights in a sleep laboratory, 25 nmol per kg intravenously or a glucose placebo given in the afternoon before the third, fourth and fifth nights. Objective sleep quality improved: higher sleep efficiency, shorter sleep latency. Subjective sleep quality did not change. The authors describe the significant effects as weak, note that part of the difference may have come from an incidental change in the placebo group, and conclude against the compound.1
Look at which measure disappeared. The machine recorded a small difference. The sleepers did not feel one.
Why does DSIP work for some people and not others?
Three reasons, all of them in the research rather than in the people posting. See why most peptides have no human evidence for the wider evidence gaps.
| What people report | What the research says about it |
|---|---|
| "It did nothing" | The blinded trial found no change in how people rated their own sleep |
| "It kept me awake" | A slight arousing effect in the first hour after injection was recorded in 19812 |
| "My ring shows more deep sleep" | Wearables estimate sleep stages from heart rate and movement, not EEG |
| "It changed my life" | The open studies found exactly this; the blinded one did not |
| "It worked at first, then stopped" | Nothing in the record addresses this; no study ran beyond seven nights |
Three things explain most of that spread.
The effect, where it exists, is small and objective. A machine detected a difference the sleepers themselves could not feel. A compound that does something measurable and unnoticeable produces exactly the split you see: some people certain it changed their life, others certain it did nothing, with no way to settle it between them.
The wakefulness is documented. The 1981 study recorded a slight arousing effect in the first hour after injection.2 People reporting that DSIP made them more awake, not less, are describing something the original researchers measured.
And nobody is taking it the way it was tested, in two separate respects covered below: not by that route, and not at that time of day.
Is anyone taking DSIP the way it was tested?
No, in two respects. Both are specific enough to check.
The route. Both human sleep trials we examined administered DSIP intravenously, and secondary accounts of the wider 1980s and 1990s literature describe it as intravenous throughout. We could not find a published human sleep trial using subcutaneous injection, the format the market sells. A different route means a different absorption curve, a different peak and different timing, and nothing establishes that the two produce the same effect.
The timing, which is the one nobody mentions. In the double-blind trial, DSIP was given in the afternoon before the nights being measured, not at bedtime.1 The 1981 study gave it intravenously and recorded sleep-promoting effects in the second hour after injection, with the sleep-enhancing capacity holding for up to six hours.2
People inject DSIP shortly before getting into bed. That puts the arousing first hour exactly where they want to be falling asleep, and it is a plausible reason the most common complaint is wakefulness rather than sedation.
Nothing establishes that afternoon dosing is correct or that bedtime dosing is wrong. What it establishes is that the protocol in the research and the protocol in the threads are not the same protocol, and the research cannot tell you what the second one does.
Who were the trials actually in?
Chronic insomniacs, which is not who is buying it, and the mismatch runs the unflattering way.
Both human studies recruited chronic insomniacs. That is the population with the most room to improve, the most measurable baseline problem, and the greatest chance of showing an effect if one exists.
Most people buying DSIP are not chronic insomniacs. They sleep adequately and want deeper sleep, better recovery, a higher number on a ring.
A drug that produced weak, unfelt improvements in people with a genuine sleep disorder has less reason to help someone who sleeps reasonably well. Ceiling effects are real: there is less to fix. Nothing has tested DSIP in healthy sleepers, so this is reasoning rather than evidence, but it runs the opposite way to how the compound is marketed.
Does my Oura ring prove DSIP is working?
Not on its own. It is not measuring the thing the trials measured.
Those trials used polysomnography: EEG electrodes reading electrical activity directly from the scalp. That is how deep sleep is defined in the first place. Delta waves are an EEG phenomenon.
An Oura ring, a Whoop strap, a Fitbit or an Apple Watch does not read EEG. It estimates sleep stages from heart rate, heart rate variability and movement, then applies a model. Those estimates correlate with polysomnography at the population level and are considerably less reliable for any individual night, particularly for distinguishing deep sleep from light sleep.
So "my deep sleep went up 20 minutes" and "slow-wave sleep increased on polysomnography" are two different claims from two different instruments. The first is not evidence for the second.
This is not a reason to ignore your own data. It is a reason not to treat it as the same measurement the studies used, and a reason to be sceptical of a night-to-night change in a number your device is least accurate at producing.
What is still missing from the research?
The first of these four gaps would settle everything.
No modern trial. The human studies cluster in the 1980s and 1990s. Nothing of comparable quality has been published since, in a field where sleep measurement has improved considerably.
No large trial. The studies are single-digit and low double-digit participant counts. A six-person open study is a reasonable way to generate a hypothesis and not a way to establish an effect.
No trial of the actual protocol. We could not find a published human sleep trial using subcutaneous injection, or one dosing at bedtime.
No receptor. No receptor for DSIP has been identified, and no gene, around fifty years after it was first isolated. Its mechanism is unknown, which is unusual for a compound with this much name recognition.
How much DSIP is being sold?
A lot, and in a format the trials never used.
DSIP appears in 112 listings across 90 sellers in our 5 October capture, at a median of $6.80 per mg among in-stock single vials. 102 of those listings are vials; the rest are sprays and solutions. The most common stated sizes are 5 mg and 10 mg.3
Ninety sellers is broad distribution for a compound whose best trial concluded it was unlikely to help. See the nootropic peptides, sorted out for the wider category.
When do sleep problems need more than a peptide?
This is the one area where self-experimentation delays real treatment, so it belongs here. Our guide to telling your doctor covers that conversation.
Loud snoring, waking unrefreshed however long you sleep, or being told you stop breathing at night. Sleep apnoea is common, treatable and routinely missed, and no peptide addresses it.
Insomnia lasting more than three months, which has a specific and effective non-drug treatment that most people are never offered.
New early waking with low mood, or sleep that changed suddenly without an obvious cause.
And anything that makes you unsafe to drive.
Common questions
Does DSIP actually work for sleep?
The strongest human trial, a double-blind placebo-controlled study in chronic insomniacs, found weak objective improvements, no change in how people rated their own sleep, and concluded that short-term treatment with DSIP is not likely to be of major therapeutic benefit. That is the authors' own conclusion about their own result.
Why does DSIP keep me awake?
The 1981 study recorded a slight arousing effect in the first hour after injection, with sleep-promoting effects appearing only in the second hour. People reporting wakefulness are describing something the original researchers measured.
Why do some people say it changed their life and others say it did nothing?
Because the measured effect is small and objective. In the blinded trial a machine detected a difference the sleepers themselves could not feel. A compound that does something unnoticeable produces exactly that split, with no way to settle it between the two camps.
My Oura ring shows more deep sleep. Does that confirm it?
Not on its own. The trials used polysomnography, which reads EEG directly from the scalp, and deep sleep is defined by EEG activity. Wearables estimate sleep stages from heart rate and movement, and are least accurate at distinguishing deep from light sleep.
Has DSIP been tested the way people use it?
Not that we could find. Both trials covered here administered DSIP intravenously, and we could not find a published human sleep trial using the subcutaneous injection the market sells.
When should DSIP be taken?
No published trial answers this for the way people use it. The double-blind study administered DSIP in the afternoon before the nights it measured, not at bedtime, and the 1981 study found sleep-promoting effects in the second hour after injection with a slight arousing effect in the first. Injecting immediately before bed puts that first hour where you are trying to fall asleep.
Was DSIP tested in people who sleep normally?
No. Both human studies recruited chronic insomniacs, which is the population with the most room to improve. A compound producing weak and unfelt gains there has less reason to help someone who already sleeps adequately, though nobody has tested that.
How old is the research?
The human sleep studies cluster in the 1980s and 1990s. Nothing of comparable quality has been published in the last two decades, despite considerable improvement in sleep measurement over that period.
What are the side effects of DSIP?
The old trials described it as well tolerated with no daytime sedation, in a handful of people over short periods. The most commonly reported effect in community accounts is the opposite of the intended one: wakefulness, which matches the arousing first hour recorded in 1981. No long-term safety data exists.
What dose of DSIP do people use?
No established dose exists for the way people take it. The published trials used 25 nmol per kilogram intravenously, which is not a figure that transfers to a subcutaneous vial, and no trial has tested the doses circulating online.
How does DSIP compare to melatonin?
Melatonin is a hormone your body makes, with a large body of human evidence, strongest for shifting sleep timing rather than deepening sleep. DSIP has two small trials from the 1980s and 1990s, the better of which concluded against it. They are not comparable bodies of evidence.
Is DSIP safe?
The old studies described it as well tolerated with no daytime sedation, in a handful of people, given intravenously, over short periods. That is not the same as a safety record, and no long-term data exists.
How is it even supposed to work?
Nobody knows. No receptor has been identified for it and no gene, around fifty years after it was first isolated from rabbit blood, and where it is synthesised in the body is also unknown.
Sources
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992;26(4):193-7. doi:10.1159/000118919. PMID 1299794. Double-blind study in 16 chronic insomniac patients, using a matched-pairs parallel-groups design, with subjects sleeping five consecutive nights in the laboratory. Conducted by a group in Amsterdam, separate from the Swiss group responsible for most of the positive DSIP literature. Half received 25 nmol/kg body weight DSIP intravenously and half a glucose placebo, before the third, fourth and fifth nights. Sleep structure, objective sleep quality by polysomnography, subjective sleep quality and subjective tiredness were assessed. Objective sleep quality indicated higher sleep efficiency and shorter sleep latency with DSIP compared with placebo, and one measure of subjective tiredness decreased in the DSIP group. The authors report that the statistically significant effects were weak and in part could be due to an incidental change in the placebo group, that no other measures including subjective sleep quality showed change, and conclude that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.
- The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia 1981;37(9):913-7. PMID 7028502. Acute intravenous administration of synthetic DSIP at 25 nmol/kg body weight in six middle-aged chronic insomniacs. Reports longer sleep duration, higher sleep quality with fewer interruptions, slightly more REM sleep, and no daytime sedation or other side effects, with sleep-enhancing capacity seen for up to six hours of night sleep. States that sleep-promoting effects occurred only in the second hour after injection, and that in the first hour a slight arousing effect was indicated. No placebo arm is described in the abstract.
- Peptide Decoding vendor price capture, 5 October 2026. peptidedecoding.com/prices. Our own data, counting one priced product at one seller as a listing. DSIP appears in 112 listings across 90 sellers: 102 vials, 7 sprays, 2 nasal sprays and 1 solution. Most common stated sizes are 5 mg and 10 mg. Among in-stock single vials priced in milligrams, the median is $6.80 per mg across 81 listings.
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology 1987;27(2):120-129. karger.com. Fourteen middle-aged chronic insomniacs, DSIP administered under placebo-controlled double-blind conditions for seven successive nights, assessing sleep and daytime performance. Reported as raising sleep efficiency to the level of normal controls. Cited as the strongest positive result in the record, and as an example of a study from the group connected to DSIP's original discovery. The 1986 study in 18 chronic insomniacs referenced in the table is Schneider-Helmert D, Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs, European Neurology 1986; its design is not stated in the abstract available to us.
Citing this page. Peptide Decoding. Does DSIP Actually Improve Deep Sleep? Trial figures as cited; listing data from the 5 October 2026 capture. https://peptidedecoding.com/guides/does-dsip-work